Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04098874 · ClinicalTrials.gov registry record · Phase 4

Bupropion for the Prevention of Postpartum Smoking Relapse

A Phase 4 study of Postpartum Smoking Relapse, sponsored by University of Minnesota.

Recruiting
Registry status
Phase 4
Development phase
200
Enrollment target
1
Study location

NCT04098874 is a Phase 4 study of Postpartum Smoking Relapse that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04098874, a Phase 4 study of Postpartum Smoking Relapse, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
Phase 4
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum. Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks post-randomization). All participants will complete the same data collection procedures (e.g., biological sample collection for hormone and cotinine analysis and completion of validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52 post-randomization.

Conditions Studied

Interventions

  • DRUG Placebo oral tablet
  • DRUG Bupropion Extended Release Oral Tablet

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2020-01-01
Est. Completion 2026-07-31
Phase Phase 4

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT04098874

The ClinicalTrials.gov registry entry for NCT04098874 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postpartum Smoking Relapse appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.

NCT04098874 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04098874 about?

NCT04098874 is a clinical study titled "Bupropion for the Prevention of Postpartum Smoking Relapse". This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum. Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once d...

What is the current status of trial NCT04098874?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-01-01. Estimated completion is 2026-07-31.

What conditions does trial NCT04098874 study?

This clinical trial studies the following conditions: Postpartum Smoking Relapse.

What interventions are being tested in trial NCT04098874?

The interventions under investigation include: Placebo oral tablet (DRUG), Bupropion Extended Release Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT04098874?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04098874 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.